Sep 14
2020
In a new study, a team of Packard scientists identified a key intersection between two major pathways of pathology in ALS and frontotemporal dementia (FTD)
Read the full article in Science Translational Medicine
Sep 3
2020
Results of a new Phase 2 randomized clinical trial in 137 patients with ALS showed that treatment with the drugs sodium phenylbutyrate and taurursodiol, combined together, could significantly slow functional decline over 24 weeks compared to placebo.
Read more about the trial in a recent article on www.nytimes.com
